120 related articles for article (PubMed ID: 30937921)
1. Endothelin-A receptor in gastric cancer and enhanced antitumor activity of trastuzumab in combination with the endothelin-A receptor antagonist ZD4054.
Shen W; Xi H; Li C; Bian S; Cheng H; Cui J; Wang N; Wei B; Huang X; Chen L
Ann N Y Acad Sci; 2019 Jul; 1448(1):30-41. PubMed ID: 30937921
[TBL] [Abstract][Full Text] [Related]
2. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Smollich M; Götte M; Fischgräbe J; Macedo LF; Brodie A; Chen S; Radke I; Kiesel L; Wülfing P
Breast Cancer Res Treat; 2010 Sep; 123(2):345-57. PubMed ID: 19943105
[TBL] [Abstract][Full Text] [Related]
3. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
Rosanò L; Di Castro V; Spinella F; Nicotra MR; Natali PG; Bagnato A
Mol Cancer Ther; 2007 Jul; 6(7):2003-11. PubMed ID: 17620430
[TBL] [Abstract][Full Text] [Related]
4. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
Rosanò L; Di Castro V; Spinella F; Tortora G; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2007 Jul; 67(13):6351-9. PubMed ID: 17616694
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models.
Shu S; Yamashita-Kashima Y; Yanagisawa M; Nakanishi H; Kodera Y; Harada N; Yoshimura Y
Anticancer Drugs; 2020 Mar; 31(3):241-250. PubMed ID: 31633500
[TBL] [Abstract][Full Text] [Related]
6. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.
Yamashita-Kashima Y; Iijima S; Yorozu K; Furugaki K; Kurasawa M; Ohta M; Fujimoto-Ouchi K
Clin Cancer Res; 2011 Aug; 17(15):5060-70. PubMed ID: 21700765
[TBL] [Abstract][Full Text] [Related]
7. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054.
Growcott JW
Anticancer Drugs; 2009 Feb; 20(2):83-8. PubMed ID: 19065106
[TBL] [Abstract][Full Text] [Related]
8. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.
Warren R; Liu G
Expert Opin Investig Drugs; 2008 Aug; 17(8):1237-45. PubMed ID: 18616419
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
11. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
13. Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer.
Xiong J; Han S; Ding S; He J; Zhang H
Oncol Rep; 2018 Mar; 39(3):1396-1404. PubMed ID: 29328489
[TBL] [Abstract][Full Text] [Related]
14. Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade.
Singh R; Kim WJ; Kim PH; Hong HJ
Exp Mol Med; 2013 Nov; 45(11):e52. PubMed ID: 24176949
[TBL] [Abstract][Full Text] [Related]
15. Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.
Moody TW; Ramos-Alvarez I; Moreno P; Mantey SA; Ridnour L; Wink D; Jensen RT
Peptides; 2017 Apr; 90():90-99. PubMed ID: 28153500
[TBL] [Abstract][Full Text] [Related]
16. miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer.
Guo J; Zhong X; Tan Q; Yang S; Liao J; Zhuge J; Hong Z; Deng Q; Zuo Q
Cell Death Dis; 2021 Jul; 12(7):696. PubMed ID: 34257270
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
[TBL] [Abstract][Full Text] [Related]
18. Salvianolic Acid A, as a Novel ETA Receptor Antagonist, Shows Inhibitory Effects on Tumor in Vitro.
Zhang Q; Wang S; Yu Y; Sun S; Zhang Y; Zhang Y; Yang W; Li S; Qiao Y
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27490540
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of endothelin A receptor expression inhibits osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse model.
Li Y; Liao Q; Li K; Zhong D; Weng X; Mi M
Mol Med Rep; 2012 Jun; 5(6):1391-5. PubMed ID: 22446894
[TBL] [Abstract][Full Text] [Related]
20. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]